Stroke RSS Page 6

Filtered By:
Condition: Atrial Fibrillation
Countries: Japan Health

This page shows you your search results in order of date. This is page number 6.

Order by Relevance | Date

Total 333 results found since Jan 2013.

Association of Concomitant Coronary Artery Disease With Cardiovascular Events in Patients With Atrial Fibrillation 　- The Fushimi AF Registry
CONCLUSIONS: In Japanese AF patients, concomitant CAD was associated with higher prevalences of major co-morbidities and higher incidences of cardiovascular events; however, history of CAD was not associated with the incidence of stroke/SE.PMID:35786691 | DOI:10.1253/circj.CJ-22-0180
Source: Circulation Journal - July 5, 2022 Category: Cardiology Authors: Nobutoyo Masunaga Hisashi Ogawa Kimihito Minami Kenjiro Ishigami Syuhei Ikeda Kosuke Doi Yasuhiro Hamatani Takashi Yoshizawa Yuya Ide Akiko Fujino Mitsuru Ishii Moritake Iguchi Hiromichi Wada Koji Hasegawa Hikari Tsuji Masahiro Esato Mitsuru Abe Masaharu Source Type: research

Clinical Characteristics of Non-Valvular Atrial Fibrillation Patients With a Large Left Atrial Appendage Ostium-Limiting Percutaneous Closure
CONCLUSIONS: NVAF patients with a large LAA ostium may have a higher risk of stroke and bleeding. LSAF and factors leading to LA overload may be closely associated with LAA ostial dilatation and can promote it.PMID:35786689 | DOI:10.1253/circj.CJ-22-0053
Source: Circulation Journal - July 5, 2022 Category: Cardiology Authors: Tomoko Machino-Ohtsuka Daishi Nakagawa Noor K Albakaa Tomofumi Nakatsukasa Naoto Kawamatsu Kimi Sato Masayoshi Yamamoto Hiro Yamasaki Tomoko Ishizu Masaki Ieda Source Type: research

Treatment strategy of dabigatran etexilate following the availability of idarucizumab in Japanese patients with non-valvular atrial fibrillation: J-Dabigatran Surveillance 2
CONCLUSIONS: Dabigatran continues to be safe and well tolerated in patients with NVAF for stroke and systemic embolism prevention and continues to be prescribed appropriately. Treatment outcomes have not changed since the availability of idarucizumab. Since the J-Dabi1 study, treatment guidelines for anticoagulation use in NVAF have been updated based on emerging clinical evidence, accounting for differences in patient characteristics, and making dabigatran a preference for distinct patient populations.PMID:35717283 | DOI:10.1016/j.jjcc.2022.04.007
Source: Journal of Cardiology - June 18, 2022 Category: Cardiology Authors: Takeshi Yamashita Shinichiro Uchiyama Hirotsugu Atarashi Ken Okumura Yukihiro Koretsune Masahiro Yasaka Junichi Wakayama Taku Fukaya Hiroshi Inoue J-Dabigatran Surveillance Investigators Source Type: research

Rationale and design of a prospective study evaluating population pharmacokinetics and pharmacodynamics of rivaroxaban in Chinese patients with non-valvular atrial fibrillation
Introduction Rivaroxaban is one of the most commonly used non-vitamin K antagonists for stroke prevention in patients with non-valvular atrial fibrillation (NVAF). Different individual exposures exist for Asian and non-Asian populations, and dose selection is different for Japanese and non-Japanese subjects. Few studies have investigated the pharmacokinetics (PK) and pharmacodynamics (PD) of rivaroxaban in Chinese patients and provided a solid reference for dose selection and individualised therapy. Methods and analysis This is a single-centre prospective study. Rivaroxaban-treated Chinese NVAF patients will be recruited ...
Source: BMJ Open - June 3, 2022 Category: General Medicine Authors: Liu, X.-Q., Zhang, Y.-F., Ding, H.-Y., Yan, M.-M., Zhong, M.-K., Ma, C.-L. Tags: Open access, Pharmacology and therapeutics Source Type: research

Incidence of atrial fibrillation in elderly patients with type 2 diabetes mellitus
CONCLUSIONS: Annually, 1 in 200 elderly Japanese patients with T2D are estimated to develop AF. Because elderly patients with T2D with AF are at an elevated risk for CVD, careful follow-up of this patient subgroup is necessary.TRIAL REGISTRATION NUMBER: NCT00110448.PMID:35361621 | DOI:10.1136/bmjdrc-2021-002745
Source: Atherosclerosis - April 1, 2022 Category: Cardiology Authors: Chisa Matsumoto Hisao Ogawa Yoshihiko Saito Sadanori Okada Hirofumi Soejima Mio Sakuma Izuru Masuda Masafumi Nakayama Naofumi Doi Hideaki Jinnouchi Masako Waki Takeshi Morimoto Source Type: research

Trends of anticoagulant use and outcomes of patients with non-valvular atrial fibrillation: Findings from the RAFFINE registry
CONCLUSIONS: The all-cause mortality, cardiovascular mortality, and incidence of major bleeding events were higher in the warfarin group than in the DOAC group. After adjustment, warfarin use was not associated with an increase in these events. Off-label dosing of DOACs is not rare and is not associated with reduced effectiveness. The impact of off-label dosing of each DOAC on clinical events should be assessed using a larger population.PMID:35346556 | DOI:10.1016/j.jjcc.2022.03.006
Source: Journal of Cardiology - March 29, 2022 Category: Cardiology Authors: Sakiko Miyazaki Katsumi Miyauchi Hidemori Hayashi Kazuo Yamashiro Ryota Tanaka Yuji Nishizaki Shuko Nojiri Satoru Suwa Masataka Sumiyoshi Yuji Nakazato Takao Urabe Nobutaka Hattori Tohru Minamino Hiroyuki Daida Source Type: research

Pages: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20